MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...
A major new market will open up following this approval. The post Good news out of China has this drug company's shares ...
The Chinese regulator has accepted the New Drug Application for Illuccix, Telix’s lead imaging agent for prostate cancer. The ...
Detailed price information for Telix Pharmaceutical Ltd (TLPPF) from The Globe and Mail including charting and trades.
Capital Brief on MSN
Telix Pharmaceuticals secures China approval for prostate cancer imaging filing
The news: Biotech company Telix Pharmaceuticals has received clearance from the Chinese National Medical Products ...
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) announced positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix, Kit for the preparation of 68Ga-PSMA-11) for ...
Management reiterated full-year 2025 total revenue guidance of $4 million to $8 million. DeLucia confirmed, "For full-year 2025, we reiterate our guidance for our total operating costs and expenses, ...
This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results